CDK12 and breast carcinoma: We found that CDK12, a previously reported gene conferring PARPi sensitivity in ovarian [43] and breast cancer [44] models, is an essential gene in all the cell lines tested without altering response to olaparib in our CRISPR-Cas9 competition assay (Supplementary Fig. 6B–G).